Patents Assigned to Emergent Product Development UK Limited
-
Patent number: 7955600Abstract: The present invention relates to vaccines, in particular, to an attenuated gram-negative cell comprising the SPI2 gene locus, wherein at least one gene of the SPI2 locus is inactivated, wherein said inactivation results in an attenuation/reduction of virulence compared to the wild type of said cell, and to a carrier for the presentation of an antigen to a host, which carrier is said attenuated gram-negative cell, wherein said cell comprises at least one heterologous nucleic acid molecule comprising a nucleic acid sequence coding for said antigen, wherein said cell is capable of expressing said nucleic acid molecule or capable of causing the expression of said nucleic acid molecule in a target cell.Type: GrantFiled: August 17, 2007Date of Patent: June 7, 2011Assignee: Emergent Product Development UK LimitedInventors: Michael Hensel, David William Holden, Jacqueline Elizabeth Shea
-
Patent number: 7887816Abstract: The present invention pertains to a Salmonella microorganism having an attenuating mutation which disrupts the expression of a gene located within the Spi2 pathogenicity island, and an auxotrophic mutation. The microorganism therefore has a double mutation which helps prevent reactivity of the microorganism while maintaining the effectiveness of the microorganism to elicit an immune response. The present invention also pertains to vaccine compositions and methods for treating and preventing a Salmonella infection in a patient.Type: GrantFiled: February 1, 2007Date of Patent: February 15, 2011Assignee: Emergent Product Development UK LimitedInventors: Robert Graham Feldman, Gordon Dougan, Joseph David Santangelo, David William Holden, Jacqueline Elizabeth Shea, Zoe Hindle
-
Patent number: 7842290Abstract: A method for identifying a microorganism having a reduced adaptation to a particular environment comprising the steps of: (1) providing a plurality of microorganisms each of which is independently mutated by the insertional inactivation of a gene with a nucleic acid comprising a unique marker sequence so that each mutant contains a different marker sequence, or clones of the said microorganism; (2) providing individually a stored sample of each mutant produced by step (1) and providing individually stored nucleic acid comprising the unique marker sequence from each individual mutant; (3) introducing a plurality of mutants produced by step (1) into the said particular environment and allowing those microorganisms which are able to do so to grow in the said environment; (4) retrieving microorganisms from the said environment or a selected part thereof and isolating the nucleic acid from the retrieved microorganisms; (5) comparing any marker sequences in the nucleic acid isolated in step (4) to the unique marType: GrantFiled: August 17, 2007Date of Patent: November 30, 2010Assignee: Emergent Product Development UK LimitedInventor: David William Holden
-
Patent number: 7700104Abstract: The present invention relates to vaccines, in particular, to an attenuated gram-negative cell comprising the SPI2 gene locus, wherein at least one gene of the SPI2 locus is inactivated, wherein said inactivation results in an attenuation/reduction of virulence compared to the wild type of said cell, and to a carrier for the presentation of an antigen to a host, which carrier is said attenuated gram-negative cell, wherein said cell comprises at least one heterologous nucleic acid molecule comprising a nucleic acid sequence coding for said antigen, wherein said cell is capable of expressing said nucleic acid molecule or capable of causing the expression of said nucleic acid molecule in a target cell.Type: GrantFiled: January 23, 2004Date of Patent: April 20, 2010Assignee: Emergent Product Development UK LimitedInventors: Michael Hensel, David William Holden, Jacqueline Elizabeth Shea
-
Publication number: 20090274717Abstract: According to the present invention, a series of genes are identified in Group B Streptococcus, the products of which may be associated with the outer surface of the organism. The genes, or functional fragments thereof, may be useful in the preparation of therapeutics, e.g. vaccines to immunize a patient against microbial infection.Type: ApplicationFiled: August 17, 2007Publication date: November 5, 2009Applicant: Emergent Product Development UK LimitedInventors: Martin John Glenton Hughes, Joseph David Santangelo, Jonathan Douglas Lane, Robert Feldman, Joanne Christine Moore, Richard James Dobson, Paul Everest, Gordon Dougan, Rebecca Kerry Wilson
-
Patent number: 7592011Abstract: A protein from Group B Streptococcus is shown to be an outer surface protein and is a useful target for antimicrobial therapy.Type: GrantFiled: September 17, 2004Date of Patent: September 22, 2009Assignee: Emergent Product Development UK LimitedInventors: Martin John Glenton Hughes, Joseph David Santangelo, Jonathan Douglas Lane, Robert Feldman, Joanne Christine Moore, Richard James Dobson, Paul Everest, Gordon Dougan, Rebecca Kerry Wilson
-
Publication number: 20080226641Abstract: According to the present invention, a series of genes are identified in Group B Streptococcus, the products of which may be located on the outer surface of the organism. The genes, or functional fragments thereof, may be useful in the preparation of therapeutics, e.g. vaccines for the immunization of a patient against microbial infection.Type: ApplicationFiled: August 17, 2007Publication date: September 18, 2008Applicant: Emergent Product Development UK LimitedInventors: Martin John Glenton Hughes, Joseph David Santangelo, Jonathan Douglas Lane, Robert Feldman, Joanne Christine Moore, Richard James Dobson, Paul Everest, Caroline Joanne Henwood, Gordon Dougan, Rebecca Kerry Wilson
-
Patent number: 7419672Abstract: According to the present invention, a series of genes are identified in Group B Streptococcus, the products of which may be associated with the outer surface of the organism. The genes, or functional fragments thereof, may be useful in the preparation of therapeutics, e.g. vaccines to immunize a patient against microbial infection.Type: GrantFiled: March 12, 2004Date of Patent: September 2, 2008Assignee: Emergent Product Development UK LimitedInventors: Martin John Glenton Hughes, Joseph David Santangelo, Jonathan Douglas Lane, Robert Feldman, Joanne Christine Moore, Richard James Dobson, Paul Everest, Gordon Dougan, Rebecca Kerry Wilson
-
Patent number: 7217415Abstract: According to the present invention, a series of genes are identified in Group B Streptococcus, the products of which may be located on the outer surface of the organism. The genes, or functional fragments thereof, may be useful in the preparation of therapeutics, e.g. vaccines for the immunization of a patient against microbial infection.Type: GrantFiled: December 22, 1999Date of Patent: May 15, 2007Assignee: Emergent Product Development UK LimitedInventors: Martin John Glenton Hughes, Joseph David Santangelo, Jonathan Douglas Lane, Robert Feldman, Joanne Christine Moore, Richard James Dobson, Paul Everest, Caroline Joanne Henwood, Gordon Dougan, Rebecca Kerry Wilson
-
Patent number: 7211264Abstract: The present invention pertains to a Salmonella microorganism having an attenuating mutation which disrupts the expression of a gene located within the Spi2 pathogenicity island, and an auxotrophic mutation. The microorganism therefore has a double mutation which helps prevent reactivity of the microorganism while maintaining the effectiveness of the microorganism to elicit an immune response. The present invention also pertains to vaccine compositions and methods for treating and preventing a Salmonella infection in a patient.Type: GrantFiled: April 8, 2004Date of Patent: May 1, 2007Assignee: Emergent Product Development UK LimitedInventors: Robert Graham Feldman, Gordon Dougan, Joseph David Santangelo, David William Holden, Jacqueline Elizabeth Shea, Zoe Hindle